Effector CD8+ T-cell engraftment and antitumor immunity in lymphodepleted hosts is IL7Rα dependent

Cancer Immunology Research

Volumn 3, Issue 12, 2015, Pages 1364-1374

  Johnson, C Bryce ^a   Riesenberg, Brian P ^a   May, Bennett R ^a   Gilreath, Stuart C ^a   Li, Guangfu ^a   Staveley O'Carroll, Kevin F ^a   Garrett Mayer, Elizabeth ^a   Mehrotra, Shikhar ^a   Cole, David J ^a   Rubinstein, Mark P ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR ALPHA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A7R34; MONOCLONAL ANTIBODY JES6 1A12; MONOCLONAL ANTIBODY M25; MONOCLONAL ANTIBODY S4B6; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; IL12A PROTEIN, MOUSE; INTERLEUKIN 12P35; INTERLEUKIN 7 RECEPTOR; INTERLEUKIN-7 RECEPTOR, ALPHA CHAIN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; EFFECTOR CELL; ENGRAFTMENT; FEMALE; HOST; HUMAN; HUMAN CELL; MALE; MOUSE; NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; WHOLE BODY RADIATION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; TRANSPLANTATION; TUMOR CELL LINE;

ADOPTIVE TRANSFER; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; HUMANS; INTERLEUKIN-12 SUBUNIT P35; INTERLEUKIN-15; INTERLEUKIN-7; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, INTERLEUKIN-7;

EID: 84962110355     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0087-T     Document Type: Article

References (49)

1. Ma A, Koka R, Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol 2006; 24: 657-79.
2. Overwijk WW, Schluns KS. Functions of gammaC cytokines in immune homeostasis: current and potential clinical applications. Clin Immunol 2009; 132: 153-65.
3. Surh CD, Sprent J. Homeostasis of naive and memory T cells. Immunity 2008; 29: 848-62.
4. Takada K, Jameson SC. Naive T cell homeostasis: from awareness of space to a sense of place. Nat Rev Immunol 2009; 9: 823-32.
5. Carrette F, Surh CD. IL-7 signaling and CD127 receptor regulation in the control of T cell homeostasis. Semin Oncol 2012; 24: 209-17.
6. Intlekofer AM, Takemoto N, Wherry EJ, Longworth SA, Northrup JT, Palanivel VR, et al. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat Immunol 2005; 6: 1236-44.
7. Vera JF, Hoyos V, Savoldo B, Quintarelli C, Giordano Attianese GM, Leen AM, et al. Genetic manipulation oftumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther 2009; 17: 880-8.
8. + T cells in vivo by IL-15. Immunity 1998; 8: 591-9.
9. + T cells. J Exp Med 2005; 202: 907-12.
10. + T cells. J Exp Med 2002; 195: 1515-22.
11. + cells. J Exp Med 2002; 195: 1523-32.
12. Becker TC, Wherry EJ, Boone D, Murali-Krishna K, Antia R, Ma A, et al. Interleukin 15isrequired for proliferative renewalofvirus-specific memory CD8 T cells. J Exp Med 2002; 195: 1541-8.
13. Hand TW, Morre M, Kaech SM. Expression of IL-7 receptor alpha is necessary but not sufficient for the formation of memory CD8 T cells during viral infection. Proc Natl Acad Sci U S A 2007; 104: 11730-5.
14. Haring JS, Jing X, Bollenbacher-Reilley J, Xue HH, Leonard WJ, Harty JT. Constitutive expression of IL-7 receptor alpha does not support increased expansion or prevent contraction of antigen-specific CD4 or CD8 T cells following Listeria monocytogenes infection. J Immunol 2008; 180: 2855-62.
15. + T-cell subsets during contraction of the immune response. Blood 2008; 112: 3704-12.
16. Curtsinger JM, Mescher MF. Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol 2010; 22: 333-40.
17. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133-46.
18. Rubinstein MP, Cloud CA, Garrett TE, Moore CJ, Schwartz KM, Johnson CB, et al. Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host. J Am Coll Surg 2012; 214: 700-7;discussion 07-8
19. + effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor. J Immunol 2000; 164: 916-25.
20. Gerner MY, Heltemes-Harris LM, Fife BT, Mescher MF. Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control. J Immunol 2013; 191: 1011-5.
21. Bergamaschi C, Bear J, Rosati M, Beach RK, Alicea C, Sowder R, et al. Circulating IL-15 exists as heterodimeric complex with soluble IL-15Ral-pha in human and mouse serum. Blood 2012; 120:e1-8.
22. Bracci L, Moschella F, Sestili P, La Sorsa V, Valentini M, Canini I, et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res 2007; 13(2 Pt 1): 644-53.
23. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26: 5233-9.
24. Palmer MJ, Mahajan VS, Chen J, Irvine DJ, Lauffenburger DA. Signaling thresholds govern heterogeneity in IL-7-receptor-mediated responses of naive CD8(+) T cells. Immunol Cell Biol 2011; 89: 581-94.
25. + T cell responses require STAT4. J Immunol 2006; 177: 7618-25.
26. + T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity 2010; 32: 67-78.
27. Hammerbeck CD, Mescher MF. Antigen controls IL-7R alpha expression levels on CD8 T cells during full activation or tolerance induction. J Immunol 2008; 180: 2107-16.
28. Joshi NS, Cui W, Chandele A, Lee HK, Urso DR, Hagman J, et al. Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity 2007; 27: 281-95.
29. Keppler SJ, Theil K, Vucikuja S, Aichele P. Effector T-cell differentiation during viral and bacterial infections: role of direct IL-12 signals for cell fate decision of CD8(+) T cells. Eur J Immunol 2009; 39: 1774-83.
30. Pearce EL, Shen H. Generation of CD8 T cell memory is regulated by IL-12. J Immunol 2007; 179: 2074-81.
31. Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN, et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest 2011; 121: 4746-57.
32. + T cells. J Exp Med 2003; 198: 569-80.
33. Mehrotra S, Al-Khami AA, Klarquist J, Husain S, Naga O, Eby JM, et al. A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice. J Immunol 2012; 189: 1627-38.
34. +melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res 2005; 65: 1570-6.
35. Norell H, Zhang Y, McCracken J, Martins da Palma T, Lesher A, Liu Y, et al. CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting. Cancer Immunol Immunother 2010; 59: 851-62.
36. Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A. Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med 2012; 209: 2351-65.
37. + T central-memory cell survival but not T effector-memory cell development. J Immunol 2011; 187: 5170-82.
38. + T cell activation by IL-2. J Immunol 2013; 191: 5559-73.
39. Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013; 38: 13-25.
40. Palmer MJ, Mahajan VS, Trajman LC, Irvine DJ, Lauffenburger DA, Chen J. Interleukin-7 receptor signaling network: an integrated systems perspective. Cell Mol Immunol 2008; 5: 79-89.
41. +IL-7Rhi T cells. Eur J Immunol 2008; 38: 30-9.
42. van Lier RA, Brouwer M, Rebel VI, van Noesel CJ, Aarden LA. Immobilized anti-CD3 monoclonal antibodies induce accessory cell-independent lym-phokine production, proliferation and helper activity in human T lymphocytes. Immunology 1989; 68: 45-50.
43. Weiss A, Manger B, Imboden J. Synergy between the T3/antigen receptor complex and Tp44 in the activation of human T cells. J Immunol 1986; 137: 819-25.
44. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 2002; 99: 16168-73.
45. Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, et al. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother 2008; 31: 742-51.
46. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-9.
47. Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol 2005; 175: 7046-52.
48. + T-cell memory and prime-boost response after dendritic-cell vaccination. Nat Med 2005; 11: 748-56.
49. Chandele A, Joshi NS, Zhu J, Paul WE, Leonard WJ, Kaech SM. Formation of IL-7Ralphahigh and IL-7Ralphalow CD8 T cells during infection is regulated by the opposing functions of GABPalpha and Gfi-1. J Immunol 2008; 180: 5309-19.